text
stringlengths 0
197k
|
|---|
<|newrecord|> nctId: NCT06383338 id: PEGASUS briefTitle: A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. acronym: PEGASUS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2026-05 date: 2024-04-25 date: 2024-04-25 name: Murdoch Childrens Research Institute class: OTHER briefSummary: PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers. |
The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications. |
The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine. conditions: Hodgkin Lymphoma conditions: Non Hodgkin Lymphoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 10 type: ESTIMATED name: Omeprazole name: Dextromethorphan measure: Proportion of patients who consent to study and complete baseline and at least two longitudinal timepoints with successful measurement of probe drug MR (Metabolic ratio) measure: Percentage of participants completing all required longitudinal blood sampling measure: Proportion of participants with successful detection of probe drug overall and at each sampling timepoint measure: Proportion of participants where phenotype can be classified according to MR overall at each sampling timepoint measure: The level of acceptability of participation in pharmacogenomic & phenoconversion testing using the PEGASUS specific survey tool (based on the Theoretical Framework of Acceptability [TFA]) measure: Percentage of participants experiencing an adverse event (AE) during probe drug administration measure: Incidence of genotype and phenotype mismatch, overall and across longitudinal timepoints measure: Proportion of participants with disease staging and biomarkers of extent of disease measure: Proportion of participants with a systemic inflammatory state measure: Proportion of participants taking medications involving the CYP P450 pathway measure: Participant demographic information measure: Proportion of participants with other environmental factors measure: Longitudinal inflammatory profile of participants with Hodgkin or non-Hodgkin Lymphoma as measured by a panel including serum levels of procalcitonin, c-reactive protein and cytokine analysis. sex: ALL minimumAge: 6 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: Peter MacCallum Cancer Centre city: Melbourne state: Victoria zip: 3000 country: Australia name: Marliese Alexander, Doctor of Philosophy role: CONTACT lat: -37.814 lon: 144.96332 hasResults: False |
<|newrecord|> nctId: NCT06383325 id: Livertoxcicity in AL briefTitle: Livertoxcicity in Acute Leukemia Patients During Chemotherapy Treatment overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-08-01 date: 2024-04-25 date: 2024-04-25 name: Assiut University class: OTHER briefSummary: Detection of hepatotoxcicity in acute leukemia and study the outcome of acute leukemia patients that suffer from hepatic toxiciyt conditions: Liver Toxicity, Chemically-Induced studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ESTIMATED name: Chemotherapy measure: Detection of hepatotoxcicity in acute leukemia during chemotherapy treatment sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383312 id: E-10840098-772.02-4248 briefTitle: Magnetic Reflexologic Insoles for Primary Dysmenorrhea overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-08 date: 2024-09 date: 2024-04-25 date: 2024-04-25 name: Istanbul Medipol University Hospital class: OTHER briefSummary: In the study, easy-to-access and easy-to-use reflexologic magnetic insoles were used in women with primary dysmenorrhea who did not want to receive medical treatment; In addition to reducing symptoms such as pain, nausea, dizziness, fainting, vomiting, weakness, constipation/acute gastroenteritis, it is aimed to increase individuals' participation in daily life activities and increase their quality of life by increasing their emotional state. conditions: Primary Dysmenorrhea studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: two groups; treatment group and sham group primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Reflexologic Magnetic Insole Group name: Orthopedic Insole Group measure: McGill Pain Questionnaire-Short Form: measure: Menstruation Attitude Questionnaire measure: Menstruation Symptom Questionnaire measure: Visual Analogue Scale (VAS) sex: FEMALE minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Istanbul Medipol University city: Istanbul zip: 34815 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False |
<|newrecord|> nctId: NCT06383299 id: AnkaraYbuMNC briefTitle: The Validity and Reliability Study of Turkish Version of Calgary Sleep Apnea Quality of Life Index overallStatus: COMPLETED date: 2021-01-01 date: 2021-07-01 date: 2021-08-01 date: 2024-04-25 date: 2024-04-25 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: The aim of this study is to investigate its validity and reliability of the questionarre whose original English name was "Calgary Sleep Apnea Quality of Life Index" which we plan to translate into Turkish as Sleep Apnea Quality of Life Index. conditions: Obstruvtive Sleep Apnea Syndrome (OSAS) studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 60 type: ACTUAL measure: Calgary Sleep Apnea Quality of Life İndex (C-SAQLI) measure: Short Form 36 measure: Epworth Sleepiness Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Yildirim Beyazıt University city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False |
<|newrecord|> nctId: NCT06383286 id: AnkaraYBUfby briefTitle: The Relationship Between Physical Activity Levels and Anxiety, Depression, Stress of Disabled Athletes overallStatus: COMPLETED date: 2020-12-01 date: 2021-03-01 date: 2022-03-01 date: 2024-04-25 date: 2024-04-25 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: It is aimed to investigate the relationship between anxiety, depression, stress and physical activities of disabled athletes prepared for the paralympic games to be held in Tokyo in 2021, 3 times in total at 2-3 months intervals, and to determine the change over time conditions: Paralympic Athletes studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 56 type: ACTUAL measure: State-Trait Anxiety Inventory (STAI) measure: The Center for Epidemiological Studies Depression Scale (CES-D) measure: Fatigue Severity Scale measure: International Physical Activity Questionnaire short form measure: Perceived Stress Scale (PSS-14) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Yıldırım Beyazıt Univercity city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False |
<|newrecord|> nctId: NCT06383273 id: MELT-3-001 briefTitle: A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2025-01 date: 2024-04-25 date: 2024-04-25 name: Melt Pharmaceuticals class: INDUSTRY name: MedTrials Incorporated name: Evolution Research Group name: Catalent name: Pharmalex briefSummary: The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300. Researchers will compare MELT-300 to a placebo (a look-alike substance that contains no drug) to see if MELT-300 works on procedural sedation in adult participants undergoing CELR. Researchers will also include a comparator SL midazolam to confirm the benefit of inclusion of ketamine in the combined drug product. |
The main questions it aims to answer are: |
1. Does MELT-300 is effective in comparison to placebo on procedural sedation for cataract surgery? |
2. To determine the effectiveness of MELT-300 compared with midazolam on procedural sedation (to determine the contribution of ketamine component and inform the risk of ketamine in MELT-300) |
3. To determine the time to achieve preoperative target sedation level with MELT-300 |
4. What medical problems do participants have when taking MELT-300 vs placebo |
Eligible participants will admitted to the study unit on Day 1. Participants will be randomized prior to surgery 4:1:1 to |
1. MELT-300 (i.e. 1 MELT-300 sublingual tablet which contains 3 mg midazolam and 50 mg of ketamine) |
2. Midazolam (i.e. 1 matching midazolam sublingual tablet which contains 3 mg midazolam) |
3. Placebo (i.e. 1 matching placebo sublingual tablet) |
Participants will receive study medication 30 (± 5) minutes, without food or water, before planned surgery start (defined as instillation of topical ocular anesthetic gel \[i.e.. 3 drops of chloroprocaine hydrochloride ophthalmic gel)\]. |
The effectiveness of MELT-300 will be performed after study medication is administered before surgery, in the course of surgery, and postoperative on Day 1 (end of surgery defined as just prior to drape removal). The safety of MELT-300 will be performed at baseline, in the course of surgery, postoperatively on Day 1, and on Day 3 ± 1 day post dose of study medication. conditions: Cataract studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center Study primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Double-masked whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 486 type: ESTIMATED name: MELT-300 sublingual tablet name: Midalozam sublingual tablet name: Placebo sublingual tablet measure: Percentage of Participants Achieving Successful Procedural Sedation measure: Percentage of Participants Requiring Rescue Sedation Medication measure: Percentage of Participants Achieving Preoperative Procedural Sedation Without Need For Rescue Sedation Medication measure: Percentage of Participants Requiring Rescue Sedation Medication Preoperatively measure: Percentage of Participants Requiring Rescue Sedation Medication Intraoperatively measure: Assessment of Sedation Scores in Participants Without Requiring Rescue Sedation Medication measure: Percentage of Participants Able to Complete the Surgery measure: Percentage of Participants Able to Complete the Surgery Without Intervention (Other Than Rescue Sedation Medication) measure: Duration to Achieve Preoperative Target Sedation (RSS level 2 or 3) measure: Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs) measure: Percentage of Participants Reporting Adverse Events Special Interest (AESIs) measure: Mean Change from Baseline in Blood Pressure (mmHg) measure: Mean Change from Baseline in Heart Rate [beats per minute (bpm)] measure: Mean Change from Baseline in Respiratory Rate (breath per minute) measure: Mean Change from Baseline in Body Temperature (degrees Fahrenheit) measure: Mean Change from Baseline in Pulse Oximetry (%) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383260 id: 009-0001-7719-1189 briefTitle: Assessing the Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Undiagnosed Young Adults:A Cross Sectional Study overallStatus: COMPLETED date: 2023-07-01 date: 2023-09-01 date: 2023-09-01 date: 2024-04-25 date: 2024-04-25 name: Jinnah Sindh Medical University class: OTHER briefSummary: To asses the prevalence of Attention deficit hyperactivity disrorder in undiagnosed young adults. conditions: Finding the Prevalence of ADHD in Undiagnosed Young Adults studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 200 type: ACTUAL name: Behavioral diagnostic measure: Assess the prevalence of undiagnosed ADHD in Young adults sex: ALL minimumAge: 18 Years maximumAge: 24 Years stdAges: ADULT facility: JSMU city: Karachi state: Sindh zip: 75330 country: Pakistan lat: 24.8608 lon: 67.0104 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-09-01 uploadDate: 2024-04-21T04:06 filename: Prot_SAP_000.pdf size: 834129 hasResults: False |
<|newrecord|> nctId: NCT06383247 id: AMU-PD-multicenter briefTitle: The Efficacy of Repetitive Transcranial Magnetic Stimulation With Precision Neuronavigation in Parkinson's Disease overallStatus: NOT_YET_RECRUITING date: 2024-11-01 date: 2028-12-31 date: 2030-12-31 date: 2024-04-25 date: 2024-04-29 name: Anhui Medical University class: OTHER briefSummary: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country. conditions: Parkinson Disease conditions: Transcranial Magenetic Stimualtion conditions: Supplementary Motor Area studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 312 type: ESTIMATED name: transcranial magnetic stimulation measure: Movement Disorder Society- Unified Parkinson's Disease Rating Scale III scores measure: Movement Disorder Society- Unified Parkinson's Disease Rating Scale Ⅰ scores measure: Movement Disorder Society- Unified Parkinson's Disease Rating Scale Ⅱ scores measure: Movement Disorder Society- Unified Parkinson's Disease Rating Scale Ⅳ scores sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cognitive Neuropsychology Lab Anhui Medical University city: Hefei state: Anhui zip: 230032 country: China lat: 31.86389 lon: 117.28083 hasResults: False |
<|newrecord|> nctId: NCT06383234 id: PAR 89/21 briefTitle: REduced Pain After Bariatric Surgery - Sleeve Gastrectomy acronym: REPABS-SG overallStatus: COMPLETED date: 2022-01-10 date: 2023-09-21 date: 2023-09-28 date: 2024-04-25 date: 2024-04-25 name: Fondazione Policlinico Universitario Campus Bio-Medico class: OTHER briefSummary: This study aims to analyze the effect of laparoscopic guided transversus abdominis plane (LG-TAP) block compared to placebo for postoperative analgesia following laparoscopic sleeve gastrectomy. One group of participants received a (LG-TAP) block with local anesthetic while the other group received (LG-TAP) block with saline solution (placebo). conditions: Pain conditions: Postoperative Pain conditions: Acute Pain conditions: Analgesia conditions: Bariatric Surgery Candidate conditions: Anesthesia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 110 type: ACTUAL name: LG-TAP block with local anesthetic name: LG-TAP block with saline solution name: Port site infiltration measure: Pain Score measure: Morphine Consumption measure: Toradol Consumption measure: Nausea and/or vomiting measure: Lenght of Hospital Stay measure: Time to walking measure: Time to first flatus measure: Surgical Complication sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario Campus Bio-medico city: Rome zip: 00128 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False |
<|newrecord|> nctId: NCT06383221 id: 83244570 briefTitle: Study of the Intervention Effect of Stepped-care Models on Depression Symptoms During Pregnancy. overallStatus: NOT_YET_RECRUITING date: 2024-05-20 date: 2025-10-20 date: 2026-03-10 date: 2024-04-25 date: 2024-04-25 name: Fangbiao Tao class: OTHER briefSummary: In this study, pregnant women were screened and managed for depression in three time windows: early pregnancy, mid-pregnancy, and late pregnancy. Pregnant women who screened positive for depression during pregnancy were dynamically enrolled in the study and stratified into randomized groups based on gestation period (early/mid/late) and randomly assigned to the intervention and control groups on a 1:1 basis. Pregnant women in the intervention group attended a three-week "mental fitness boot camp" and were assessed at 3 weeks, and if they still screened positive for depression, they were offered 4 times one-on-one counseling sessions by the obstetrician. The control group received routine care. conditions: Perinatal Depression conditions: Stepped Care studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 600 type: ESTIMATED name: "Mental Fitness Boot Camp - Advanced Counseling" Step-by-Step Care measure: Edinburgh Postnatal Depression Scale measure: Generalized Anxiety Disorder measure: World Health Organization Five-item Well-Being Index sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383208 id: 2024-ZF-13 briefTitle: Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on Metabolomics acronym: CRUISE-MET overallStatus: RECRUITING date: 2024-04-01 date: 2027-03-31 date: 2027-03-31 date: 2024-04-25 date: 2024-04-25 name: China-Japan Friendship Hospital class: OTHER briefSummary: Coronary heart disease (CHD) combined with chronic kidney disease (CKD) affects a substantial portion of the population and carries a significant disease burden, often leading to poor outcomes. Despite efforts to strictly control traditional risk factors, the efficacy in improving outcomes for patients with both CHD and CKD has been limited. Recent advancements in lipid metabolism research have identified new lipid metabolites associated with the occurrence and prognosis of CHD and CKD. Our preliminary trial has shown that levels of certain lipid metabolites, such as Cer(18:1/16:0), HexCer(18:1/16:0), and PI(18:0/18:1), are notably elevated in patients with CHD and reduced kidney function compared to those with relatively normal kidney function. This suggests that dysregulation of these non-traditional lipid metabolites may contribute to residual risk for adverse outcomes in these patients. |
Furthermore, the emerging concept of "cardiovascular-kidney-metabolic syndrome" and the availability of new treatment options highlight the urgent need for a risk stratification tool tailored to modern management strategies and treatment goals to guide preventive measures effectively. To address this, we propose to conduct a prospective cohort study focusing on CHD combined with CKD. This study aims to comprehensively understand the clinical characteristics, diagnosis, treatment status, and cardiovascular-kidney prognosis in these patients. Through advanced metabolomics analysis, we seek to identify lipid metabolism profiles and non-traditional lipid metabolites associated with the progression of coronary artery disease in CHD-CKD patients. Leveraging clinical databases and metabolomics data, we will develop a robust risk prediction model for adverse cardiovascular-kidney outcomes, providing valuable guidance for clinical diagnosis, treatment decisions, and ultimately improving patient prognosis. conditions: Chronic Kidney Diseases conditions: Coronary Heart Disease conditions: Lipid Metabolism Disorders studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 470 type: ESTIMATED name: lipid metabolomics measure: Incidence of cardiovascular adverse events measure: Incidence of Renal composite endpoint event measure: Incidence of All-cause mortality measure: Incidence of Repeat revascularization measure: Incidence of bleeding sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China-Japan Friendship Hospital status: RECRUITING city: Beijing state: Beijing country: China name: Chen Qiang, MD role: CONTACT phone: +86 13882712184 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False |
<|newrecord|> nctId: NCT06383195 id: SBA 24/189 briefTitle: The Reliability and Validity of the Ankylosing Spondylitis Performance Index (ASPI) in Enthesitis-Related Arthritis overallStatus: RECRUITING date: 2024-03-21 date: 2026-03-20 date: 2026-03-20 date: 2024-04-25 date: 2024-04-25 name: Hacettepe University class: OTHER briefSummary: This study assesses the test-retest reliability, construct validity, and minimal detectable change of the Ankylosing Spondylitis Performance Index (ASPI) in assessing the physical function of patients with Enthesitis-related arthritis (ERA). conditions: Enthesitis Related Arthritis conditions: Enthesitis Related Arthritis, Juvenile studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 40 type: ESTIMATED measure: Ankylosing Spondylitis Performance Index (ASPI) measure: Childhood Health Assessment Questionnaire (CHAQ) measure: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) measure: Bath Ankylosing Spondylitis Functional Index (BASFI) measure: Bath Ankylosing Spondylitis Metrology Index (BASMI) measure: Modified Paediatric Mini Mental Scale (MPMMS) sex: ALL minimumAge: 7 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Hacettepe University status: RECRUITING city: Ankara country: Turkey name: Sinan Buran, RA role: CONTACT email: [email protected] lat: 39.91987 lon: 32.85427 hasResults: False |
<|newrecord|> nctId: NCT06383182 id: Y (2024) 054 briefTitle: Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion overallStatus: NOT_YET_RECRUITING date: 2024-05-07 date: 2026-12-30 date: 2026-12-30 date: 2024-04-25 date: 2024-04-25 name: General Hospital of Shenyang Military Region class: OTHER briefSummary: Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays. conditions: Ischemic Stroke studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: endovascular treatment measure: Dynamic changes in serum biomarkers after endovascular treatment measure: favourable functional outcome, defined as modified Rankin Scale (mRS) 0-2 measure: excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1 measure: distribution of modified Rankin Scale (mRS) score measure: early neurological improvement, defined as 4 or more decrease in National Institute of Health stroke scale (NIHSS) measure: changes in National Institute of Health stroke scale (NIHSS) measure: symptomatic intracranial hemorrhage (sICH) measure: occurence of new stroke or other vascular events measure: the association between cerebral circulation time (CCT) and clinical outcomes measure: the association between serum biomarkers and clinical outcomes measure: the association between serum biomarkers and status of vessel recanalization sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: General Hospital of Northern Theater Command city: ShenYang zip: 110840 country: China lat: 41.79222 lon: 123.43278 hasResults: False |
<|newrecord|> nctId: NCT06383169 id: wanglizhong briefTitle: Impact of External Drainage of the Lumbar Cistern in Patients With Hydrocephalus Following Meningioma Surgery and Its Influence on Patient Satisfaction overallStatus: COMPLETED date: 2019-05-01 date: 2022-05-01 date: 2022-05-30 date: 2024-04-25 date: 2024-04-25 name: First Hospital of Zhangjiakou City class: OTHER briefSummary: This study aims to investigate the effect of external lumbar cistern drainage in preventing postoperative hydrocephalus in patients who have undergone meningioma surgery and its impact on patient satisfaction. conditions: Investigate the Effect of External Lumbar Cistern Drainage in Preventing Postoperative Hydrocephalus in Patients Who Have Undergone Meningioma Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 86 type: ACTUAL measure: Comparison of general clinical data measure: Comparison of the response rate measure: Comparison of GCS scores and intracranial pressure measure: Comparison of KPS scores and satisfaction sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: First Hospital of Zhangjiakou City city: Zhangjiakou country: China lat: 40.81 lon: 114.87944 hasResults: False |
<|newrecord|> nctId: NCT06383156 id: MD157/2023 briefTitle: The Use of Lung US, Fluoroscopy and Auscultation to Confirm Proper Positioning of Left Sided DLT : A Comparative Study overallStatus: NOT_YET_RECRUITING date: 2024-04-17 date: 2024-09-18 date: 2024-10-01 date: 2024-04-25 date: 2024-04-25 name: Ain Shams University class: OTHER briefSummary: The aim of this study is to compare between The Use of Lung ultrasound, Fluoroscopy and Auscultation to Confirm Proper Positioning of Left Sided DLT in elective thoracic surgeries. conditions: Endotracheal Tube Wrongly Placed During Anesthetic Procedure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 90 type: ESTIMATED name: Double lumen endotracheal tube measure: the specificity in confirming the position of the LDLT and matching the observation of flexible bronchoscope measure: sensitivity and accuracy in confirming the position of the LDLT. sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False |
<|newrecord|> nctId: NCT06383143 id: AC-020-IT briefTitle: Promoting Diagnosis and Management of AL in Italy (ProDigALIty) acronym: ProDigALIty overallStatus: RECRUITING date: 2023-05-01 date: 2025-05-01 date: 2025-05-01 date: 2024-04-25 date: 2024-04-25 name: IRCCS Policlinico S. Matteo class: OTHER briefSummary: We plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: |
1. Implement a biomarker-based screening strategy to promote early diagnosis of AL amyloidosis among at-risk patients, including patients with monoclonal gammopathy of undetermined significance, MGUS, and altered free light chain ratio (aFLCR), and patients with smoldering multiple myeloma (SMM) |
2. Expedite and facilitate patients' referral and their enrollment in ongoing pre-clinical/clinical studies, also to reflect a broader spectrum of the real-world population of patients with AL amyloidosis in Italy; |
3. Investigate the clinical utility of novel diagnostic technologies, including light chain sequencing and N-glycosylation analysis conditions: AL Amyloidosis conditions: Smoldering Multiple Myeloma conditions: Monoclonal Gammopathy of Undetermined Significance studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 760 type: ESTIMATED name: no intervention measure: Assess proportion of patients with newly diagnosed AL identified through the biomarker-based screening of at-risk patient measure: Assess the proportion of patients with deep haematological response after frontline therapy (best response evaluation) in the new enhanced, contemporary, real-world series of AL patients enrolled during the study. measure: 3. Identify associations of clonal light chain features with different clinical features at baseline. measure: Description of the baseline characteristics and 6-months outcome, as well as the time to AL development for patients with AL identified through the biomarker-based screening measure: Description of the baseline characteristics of MGUS/SMM patients with abnormal FLCR measure: Identification of clinical and biological correlates of hematological response measure: To verify whether implementing a dedicated pipeline for referral of AL patients to the National Referral Center will increase the proportion of patients from spoke centers measure: Identification of associations of clonal light chain features with event-free survival measure: Validation of existing algorithms for predicting AL amyloidosis status sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azienda Ospedaliera Policlinico Consorziale status: RECRUITING city: Bari country: Italy name: PELLEGRINO MUSTO, MD role: CONTACT phone: 080 5593471 email: [email protected] name: PELLEGRINO MUSTO, MD role: PRINCIPAL_INVESTIGATOR name: Angela Minervini, MD, PhD role: SUB_INVESTIGATOR lat: 41.11148 lon: 16.8554 facility: Azienda Ospedaliero Universitaria Policlinico G.Rodolico - San Marco status: RECRUITING city: Catania country: Italy name: Francesco Di Raimondo, MD role: CONTACT phone: 095/378.1956 email: [email protected] name: Francesco Di Raimondo, MD role: PRINCIPAL_INVESTIGATOR name: Concetta Maria Sebastiana Conticello, MD, PhD role: SUB_INVESTIGATOR lat: 37.49223 lon: 15.07041 facility: Fondazione Irccs Policlinico San Matteo status: RECRUITING city: Pavia country: Italy name: GIOVANNI PALLADINI, MD, PhD role: CONTACT phone: +390382502994 email: [email protected] name: GIOVANNI PALLADINI, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Luca Arcaini, MD role: PRINCIPAL_INVESTIGATOR name: Mario Ulisse Nuvolone, MD, PhD role: SUB_INVESTIGATOR lat: 45.19205 lon: 9.15917 facility: EMATOLOGIA - Città della Scienza e Salute - Torino status: RECRUITING city: Torino country: Italy name: FRANCESCA MARIA GAY, MD, PhD role: CONTACT phone: 011.633.5550 - 5935 email: [email protected] name: FRANCESCA MARIA GAY, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Stefania Oliva, MD, PhD role: SUB_INVESTIGATOR lat: 45.07049 lon: 7.68682 hasResults: False |
<|newrecord|> nctId: NCT06383130 id: 24SM8792 briefTitle: London Asthma Diagnostics Study acronym: LADS overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2026-07 date: 2024-04-25 date: 2024-04-25 name: Imperial College London class: OTHER name: Asthma UK name: General Practitioners Research Institute briefSummary: The goal of this trial is to learn if the addition of oscillometry with reversibility testing increases diagnostic accuracy in adult asthma diagnosis, when added to current standard of care tests: spirometry with reversibility testing and Fractional Exhaled Nitric Oxide (FeNO). The main question it aims to answer is: |
- Does oscillometry with reversibility testing increase diagnostic accuracy in detection of asthma in adults when added to spirometry with reversibility and FeNO? |
Researchers will evaluate the diagnostic accuracy of this approach with the reference standard, which is a clinically adjudicated diagnosis of asthma by two respiratory clinicians based on history and investigation results. |
Participants will |
* Undergo oscillometry testing alongside their routine asthma investigations within their scheduled clinic visit |
* Optionally participate in our sub-studies on new breath and nasal swab tests for asthma |
* Optionally participate in our qualitative substudy on patients views and attitudes to asthma testing and oscillometry conditions: Asthma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 225 type: ESTIMATED name: Oscillometry with reversibility testing name: Breath volatile testing name: Nasal eosinophil peroxidase name: Handheld capnometry measure: To evaluate the diagnostic accuracy (sensitivity, specificity) of a combination of oscillometry ± reversibility, spirometry ± reversibility and FeNO measure: To conduct an analysis comparing the diagnostic accuracy of (i) oscillometry ± reversibility with spirometry ± reversibility, (ii) spirometry±reversibility with FeNO and (iii) oscillometry ±reversibility and FeNO measure: To compare the concordance of positive and negative test results for (i) oscillometry±reversibility, (ii) spirometry ±reversibility and (iii) Fractional Exhaled Nitric Oxide (FeNO) measure: To collect data on (i) testing time, (ii) testing burden, (iii) general feasibility of implementation of the asthma diagnostic tests measure: To evaluate the diagnostic accuracy of the targeted reactive aldehyde species (RASP) panel in breath for asthma diagnosis measure: To evaluate the diagnostic accuracy of nasal biomarker eosinophil peroxidase (EPX) measure: To evaluate the diagnostic accuracy of tidal breath CO2 waveforms using the N-Tidal handheld capnometry device sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Imperial College Healthcare NHS Trust city: London zip: W2 1PG country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Imperial College Healthcare NHS Trust city: London zip: W21NY country: United Kingdom name: Eleanor Quek, MBBS role: CONTACT phone: 07411429994 email: [email protected] name: Salman Siddiqui, PhD role: CONTACT email: [email protected] name: Salman Siddiqui, PhD role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 facility: Nottingham University Hospitals NHS Trust city: Nottingham zip: NG7 2UH country: United Kingdom name: Matthew Martin, PhD role: CONTACT email: [email protected] name: Matthew Martin, PhD role: SUB_INVESTIGATOR lat: 52.9536 lon: -1.15047 hasResults: False |
<|newrecord|> nctId: NCT06383117 id: UL1TR002378 type: NIH link: https://reporter.nih.gov/quickSearch/UL1TR002378 id: KL2TR002381 type: NIH link: https://reporter.nih.gov/quickSearch/KL2TR002381 briefTitle: Understanding Effects of Calcium on the Gut-Bone Axis overallStatus: COMPLETED date: 2023-10-17 date: 2024-02-23 date: 2024-02-23 date: 2024-04-25 date: 2024-04-25 name: University of Georgia class: OTHER name: National Center for Advancing Translational Sciences (NCATS) briefSummary: The study team is inviting 13 healthy people to complete a study to explore how calcium affects hormones and bones after eating. Participants will be asked to complete two study visits within eight weeks. Before each visit, participants will be asked to not eat or drink (except water) for 9 hours. At each visit, participants will eat the same meal provided by the research team. Along with their meal, they will take a pill - in one session, this will be a calcium supplement, and in the other, a placebo (a pill with no calcium), but they won't know which one they are taking at which session. A phlebotomist will draw blood before the meal and pill, then again several times after eating. Blood draws will take place over three hours. During that time, participants will complete questionnaires about health, diet, and physical activity. |
Blood will be analyzed to check on various health indicators, like bone health markers and certain hormones, to see how they change after the meal. The difference in these health indicators between the calcium and placebo sessions will help the study team understand the impact of calcium on health after eating. This could help increase knowledge of the impact of calcium on hormones and bone health. conditions: Healthy conditions: Adult conditions: Calcium conditions: Bone Resorption conditions: Endocrine; Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomized placebo crossover trial primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Investigator, participants, team distributing pills blinded to treatment arm whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 14 type: ACTUAL name: Calcium carbonate name: Placebo Control measure: Difference in GIP (gastric inhibitory peptide) area under the curve between calcium and placebo measure: Difference in GLP-1 (glucagon-like peptide 1) area under the curve between calcium and placebo measure: Difference in CTX (carboxy-terminal collagen crosslinks) area under the curve between calcium and placebo measure: Difference in P1NP (N-terminal propeptide) area under the curve between calcium and placebo measure: Difference in insulin area under the curve between calcium and placebo measure: Difference in glucose area under the curve between calcium and placebo measure: Difference in PTH (parathyroid hormone) area under the curve between calcium and placebo sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: University of Georgia Clinical and Translational Research Unit city: Athens state: Georgia zip: 30606 country: United States lat: 33.96095 lon: -83.37794 hasResults: False |
<|newrecord|> nctId: NCT06383104 id: MyoLupus briefTitle: Myofascial Techniques and Proprioceptive Neuromuscular Facilitation in Patients With Systemic Lupus Erythematosus. overallStatus: RECRUITING date: 2024-04-22 date: 2024-05-28 date: 2024-06-26 date: 2024-04-25 date: 2024-04-25 name: Universidad Católica San Antonio de Murcia class: OTHER briefSummary: Introduction. Systemic lupus erythematosus is an autoimmune disease. The musculoskeletal system is affected in 90% of patients. The most common manifestations are myalgias, arthralgias and arthritis. |
Objective. To analyse the efficacy of an intervention using myofascial techniques and proprioceptive neuromuscular facilitation in patients with systemic lupus erythematosus. |
Methods. Randomised clinical study with 20 patients with systemic lupus erythematosus, randomised to an experimental and control group. The intervention will last 4 weeks, with a periodicity of 2 weekly sessions of 50 minutes each. The intervention of the experimental group will consist of a protocol using myofascial and proprioceptive neuromuscular facilitation techniques. |
Expected results. Improvement of knee and ankle pain intensity, functional capacity, basic mobility skills, strength, balance, agility and fatigue. conditions: System; Lupus Erythematosus studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Intervention measure: Change from baseline joint pain after treatment and at 4 weeks measure: Change from baseline functional capacity after treatment and at 4 weeks measure: Change from baseline functionality after treatment and at 4 weeks measure: Change from baseline joint pain after treatment and at 4 weeks sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Universidad Católica San Antonio, Murcia status: RECRUITING city: Murcia zip: 30107 country: Spain name: RUBEN CUESTA-BARRIUSO, PhD role: CONTACT phone: +34 968278545 email: [email protected] lat: 37.98704 lon: -1.13004 hasResults: False |
<|newrecord|> nctId: NCT06383091 id: IRB00380938 briefTitle: Impact of Manual Therapy on Laryngeal Function Following Total Thyroidectomy acronym: Man Total Thy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-12 date: 2026-12 date: 2024-04-25 date: 2024-04-25 name: Johns Hopkins University class: OTHER briefSummary: In this clinical trial, the investigators are seeking to learn if a course of voice therapy, including neck massage, stretches and pain science education in addition to voice exercise and scar massage will effectively treatment patient complaints of swallowing or voice changes after total thyroidectomy as compared to voice exercise and scar massage alone. |
The main questions it aims to answer are: |
Will neck massage, stretches and pain science education reduce patient complaints of swallowing changes after total thyroidectomy? |
Will neck massage, stretches and pain science education reduce patient complaints of voice changes after total thyroidectomy? |
Will neck massage, stretches and pain science education reduce patient complaints of scar tethering and quality changes after total thyroidectomy? |
Will neck massage, stretches and pain science education improve quality of life after total thyroidectomy? |
Participants will: |
Participate in 4 visits with the participant's endocrine/laryngology surgeon. One prior and 3 after surgery for endoscopic evaluation and tests. |
Participate in 5 Speech-Language Pathology Sessions for intervention exercises and tests. One prior and 4 after surgery. |
Complete a journal of the participant's Home Exercise Practice conditions: Total Thyroidectomy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is meant to be a parallel study. However, The Speech Language Pathologists will not be blinded as the Speech Pathologists are providing each regimen. If a participant in either group requires more intensive sessions or a differing regimen given the severity of complaints, the participants will receive it as per the recommendation of the Speech-Language Pathologist so as not to unblind the PI. An intent to treat analysis will be performed to accurately describe the data in the case of crossover and/or dropout. primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 20 type: ESTIMATED name: Anterior Neck Manual Therapy name: Pain Neuroscience Education name: Neck Stretches name: Scar massage name: Voice Exercises name: Placebo Anterior Neck Manual Therapy name: Placebo Pain Neuroscience Education name: Placebo Neck Stretches measure: Acoustic measures of voice clarity measure: Acoustic measures of speaking voice pitch measure: Acoustic measures of speaking voice quality subjectively measure: Swallowing Quality of Life as assessed by the Eating Assessment Tool - 10 measure: Laryngeal sensation measure: Scar Tethering Distance measure: Scar Quality as assessed by The Patient and Observer Scar Assessment Scale measure: Voice Quality of Life as measures by the Voice Related Quality of Life - 10 measure: Adverse Effects in the Experimental Group sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Johns Hopkins Hospital city: Baltimore state: Maryland zip: 21287 country: United States name: Claire Ligon, Masters of Education role: CONTACT phone: 434-390-6387 email: [email protected] name: Kristine Pietsch, Masters of Arts role: CONTACT phone: 518-461-3610 email: [email protected] name: Claire Ligon, Masters of Education role: SUB_INVESTIGATOR name: Kristine Pietsch, Masters of Arts role: SUB_INVESTIGATOR name: Michelle Wilson, Masters of Science role: SUB_INVESTIGATOR lat: 39.29038 lon: -76.61219 facility: Suburban Hospital city: Bethesda state: Maryland zip: 20817 country: United States name: Claire Ligon, Masters of Education role: CONTACT phone: 434-390-6387 email: [email protected] name: Vaninder Dhillon, Medical Doctor role: CONTACT phone: 925-360-5939 email: [email protected] name: Vaninder Dhillon, Medical Doctor role: PRINCIPAL_INVESTIGATOR name: Claire Ligon, Masters of Education role: SUB_INVESTIGATOR name: Michelle Wilson, Masters of Science role: SUB_INVESTIGATOR lat: 38.98067 lon: -77.10026 hasResults: False |
<|newrecord|> nctId: NCT06383078 id: MA-PC-II-012 briefTitle: HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2027-03-01 date: 2027-12-30 date: 2024-04-25 date: 2024-04-25 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer. conditions: Efficacy and Safety studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: HR070803 name: Oxaliplatin name: Tegafur name: Folinic acid name: 5-Fluorouracil measure: 1-year Disease-free survival rate measure: Overall survival (OS) measure: Disease-free survival（DFS） sex: ALL minimumAge: 20 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383065 id: YDU/2020/76-1007 briefTitle: Respiratory Physiotherapy in Type 2 Diabetes and Bariatric Surgery overallStatus: COMPLETED date: 2020-02-01 date: 2021-04-30 date: 2022-01-30 date: 2024-04-25 date: 2024-04-25 name: Near East University, Turkey class: OTHER briefSummary: The aim of this study is to investigate the early effects of Inspiratory Muscle Training (IMT) applied before and after bariatric surgery on respiratory function, respiratory muscle strength and functional capacity in individuals with type 2 diabetes. |
The study will be conducted with 40 individuals with type 2 diabetes aged between 25-65. Individuals will be randomly assigned to the IMT (trained at 30% of maximum inspiratory pressure with an IMT threshold device) and control group. As measurement parameters, a 6-minute walk test for functional capacity, a spirometry test for respiratory function, and a portable device (Cosmed Pony FX Desktop Spirometer, USA) will be used for respiratory muscle strength. Hand grip strength will be measured with a Baseline dynamometer. All measurements will be repeated on the first day before surgery and on the fourth day before discharge after surgery. conditions: Type 2 Diabetes conditions: Bariatric Surgery Candidate studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ACTUAL name: IMT Group measure: Respiratory Muscle Strength measure: Respiratory Function measure: Functional Capacity: The 6-minute walk test measure: Hand Grip Strength sex: ALL minimumAge: 25 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Near East University city: Nicosia country: Cyprus lat: 35.17531 lon: 33.3642 hasResults: False |
<|newrecord|> nctId: NCT06383052 id: NYM032Z01 briefTitle: A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC overallStatus: RECRUITING date: 2024-04-30 date: 2024-11-30 date: 2024-11-30 date: 2024-04-25 date: 2024-04-25 name: Norroy Bioscience Co., LTD class: INDUSTRY briefSummary: 177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA. conditions: Metastatic Castration-resistant Prostate Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: 177Lu-NYM032 injection measure: Number of Patients With Dose Limiting Toxicity (DLT) measure: Maximum Tolerated Dose (MTD) sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affliated Hospital of Jiangnan University status: RECRUITING city: Wuxi zip: 214000 country: China name: Chunjing Yu role: CONTACT phone: 15312238622 email: [email protected] lat: 31.56887 lon: 120.28857 hasResults: False |
<|newrecord|> nctId: NCT06383039 id: ZSoy briefTitle: Transcranial Direct Current Stimulation and Balance acronym: tDCS overallStatus: COMPLETED date: 2022-05-16 date: 2022-09-06 date: 2023-05-13 date: 2024-04-25 date: 2024-04-25 name: Zeynep Soy class: OTHER briefSummary: Postural control is an adaptive sensorimotor process involving continuous integration of sensory information from three channels. These; visual, somatosensory (proprioceptive) and vestibular senses. The study will be carried out at Istanbul Medipol University. 30 healthy individuals between the ages of 18-25 will be included. To each individual Anodal-supplementary motor area tDCS, Anodal-cerebellar tDCS, Sham tDCS applications will be cross-applied. tDCS application will take 20 minutes and each individual will receive 3 sessions in total. There will be a 72-hour rest period between sessions. Individuals assessed with Demographic Information Form for demographic information, Wii-Fit and Balance Error Scoring System for Static Balance Evaluation, Star Balance Test and Timed Get Up and Go Test for Dynamic Balance Assessment. The aim of this study is to investigate the effect of transcranial direct current stimulation applied on the supplementary motor area and cerebellum on static and dynamic balance in healthy individuals. conditions: Balance studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: All participants received 3 different interventions at different times. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants were not informed which type of current was applied. whoMasked: PARTICIPANT count: 30 type: ACTUAL name: Transcranial Direct Current Stimulation measure: Demographic Information Form measure: Wii-Fit measure: balance error scoring system measure: star excursion balance test measure: Time Up & Go Test sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Istanbul Medipol University city: Istanbul state: Beykoz country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False |
<|newrecord|> nctId: NCT06383026 id: PRO00047199 briefTitle: Transgender and Gender-Diverse Breast Cancer Screening Pilot overallStatus: RECRUITING date: 2024-04-17 date: 2027-12 date: 2028-02 date: 2024-04-25 date: 2024-04-25 name: Medical College of Wisconsin class: OTHER briefSummary: This investigation is a prospective breast cancer screening study open to all transgender and gender-diverse persons (regardless of sex assigned at birth). Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with gender-affirming therapy and family cancer history and 2) investigate TGD persons perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 130 type: ESTIMATED name: Breast Cancer Screening name: Survey/Interview name: Focus Group measure: Callback and Biopsy Rates after Breast Cancer Screening measure: Reflexive Thematic Analysis of the Physical, Cognitive, and Emotional Experience of Breast Cancer Screening in Transgender and Gender Diverse Persons measure: Reflexive Thematic Analysis on the Individual & System-Level Barriers to Breast Cancer Screening sex: ALL minimumAge: 30 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical College of Wisconsin status: RECRUITING city: Milwaukee state: Wisconsin zip: 53226 country: United States name: Chandler S Cortina, MD, MS role: CONTACT email: [email protected] lat: 43.0389 lon: -87.90647 hasResults: False |
<|newrecord|> nctId: NCT06383013 id: BB-101-BBCBB1A briefTitle: Phase II Study of BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers overallStatus: RECRUITING date: 2024-02-29 date: 2027-12-31 date: 2028-12-31 date: 2024-04-25 date: 2024-04-25 name: Blue Blood Biotech Corp. class: INDUSTRY briefSummary: This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer. conditions: Diabetic Foot Ulcer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 96 type: ESTIMATED name: BB-101 measure: Efficacy Evaluation measure: Safety Evaluation measure: Secondary Efficacy Evaluation measure: Exploratory Objectives sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare status: RECRUITING city: Taipei country: Taiwan name: Shug-Cheng Chang, MD role: CONTACT lat: 25.04776 lon: 121.53185 hasResults: False |
<|newrecord|> nctId: NCT06383000 id: BLZ2024MOH briefTitle: Assessment of Effectiveness of Continuous Non-invasive Haemodynamic Monitor by Compared to Invasive Blood Pressure and Pulse Oximeter Monitoring on Patients Undergoing General Anesthesia Surgeries for More Than 60 Minutes overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2024-12-31 date: 2024-04-25 date: 2024-04-25 name: BLZ Technology (Wuhan) Co.,Ltd class: INDUSTRY briefSummary: The goal of this observational study is to assess whether the continuous non-invasive haemodynamic monitor MOH200 (measuring blood pressure as well as pulse rate) is effective or not in people undergoing general anesthetic surgeries for more than 60 minutes with planned invasive blood pressure and pulse oximeter monitoring. |
Researchers will compare blood pressure data derived from MOH200 to the invasive blood pressure (IBP) data to see if the MOH200 is effective to measure the blood pressure of a surgical person. Also, researchers will compare pulse rate data drived from MOH200 to that from the pulse oximeter to see if the MOH200 is effective to measure the pulse rate of a surgical person. |
Participants will be asked to be applied with MOH200 monitoring while IBP monitoring and pulse oximeter are applied. And after 30 minutes of the surgery, researchers will monitor the adverse effects occurred on the skin of participants to assess the safety of MOH200. conditions: General Anesthesia conditions: Blood Pressure conditions: Pulse Rate conditions: Arterial Line studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 55 type: ESTIMATED measure: Continuous Non -invasive Blood Pressure Measurement from MOH200 measure: Invasive Blood Pressure Measurement from Arterial Line measure: Pulse Rate Measurement from MOH200 measure: Pulse Rate Measurement from Pulse Oximeter measure: The Occurrence of Pressure Pores sex: ALL minimumAge: 4 Years maximumAge: 80 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06382987 id: IM011-1124 briefTitle: A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) acronym: RePhlect overallStatus: RECRUITING date: 2024-01-22 date: 2029-12-31 date: 2029-12-31 date: 2024-04-25 date: 2024-04-25 name: Bristol-Myers Squibb class: INDUSTRY briefSummary: This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast. conditions: Plaque Psoriasis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED name: Deucravacitinib name: Apremilast measure: Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib. measure: Number of participants who achieved Physician's Global Assessment (PGA) of 0/1 from baseline to follow-up measure: Number of participants who achieved Absolute Psoriasis Area and Severity Index (aPASI) of ≤2 from baseline to follow-up measure: Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0 /1 from baseline to follow-up measure: Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation) measure: Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib or apremilast measure: Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0/1 from baseline to follow-up measure: Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation) from baseline to follow-up measure: Number of participants treated with deucravacitinib with a change in Physician's Global Assessment (PGA) from baseline to follow-up measure: Number of participants treated with deucravacitinib with a change in Dermatology Life Quality Index (DLQI) from baseline to follow-up measure: Number of participants achieving a Dermatology Life Quality Index (DLQI) score of ≤5 from baseline to follow-up measure: Number of participants who achieve a Psoriasis Area Severity Index (PASI) response of 75 from baseline to follow-up measure: Number of participants who achieve a Psoriasis Area Severity Index (PASI) response of 90 from baseline to follow-up measure: Number of participants who achieve an absolute Psoriasis Area Severity Index (aPASI) score ≤5 from baseline to follow-up measure: Number of participants who achieve an absolute Psoriasis Area Severity Index (aPASI) score ≤3 from baseline to follow-up measure: Number of participants who achieve a National Psoriasis Foundation (NPF) Acceptable Body Surface Area response from baseline to follow-up measure: Number of participants who achieve an absolute scalp-specific Physician's Global Assessment (ss-PGA) of 0/1 from baseline to follow-up measure: Number of participants who achieve an absolute Physician's Global Assessment-Fingernail (PGA-F) of 0/1 from baseline to follow-up measure: Number of participants who achieve an absolute Palmoplantar Physician's Global Assessment (pp-PGA) of 0/1 from baseline to follow-up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mebix. Inc. status: RECRUITING city: Minato-ku state: Tokyo zip: 1070052 country: Japan name: Minoru Tonogai, Site 0001 role: CONTACT lat: 34.2152 lon: 135.1501 facility: Fukuoka University Hospital status: RECRUITING city: Fukuoka country: Japan lat: 33.6 lon: 130.41667 hasResults: False |
<|newrecord|> nctId: NCT06382974 id: 3-3-14 briefTitle: Evaluation of the Osteoinductivity of Atorvastatin Combined With β-TCP overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2026-03 date: 2024-04-25 date: 2024-04-25 name: Cairo University class: OTHER briefSummary: This case series study aims to evaluate the local effects of Atorvastatin (which belongs to the family of lipid-lowering drugs, known as statins) combined with β-TCP (which is a synthetic osteoconductive bone graft), on the volume of the residual bone defects and on hastening the bone regeneration after radicular jaw cyst enucleation using CBCT-based volumetric analysis to calculate the shrinkage rate of these defects. conditions: Infection conditions: Bone Loss studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A case series study. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Cyst enucleation and bone grafting measure: Shrinkage Rate measure: Inflammation sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Cairo University city: Cairo country: Egypt role: CONTACT phone: 23634965 email: [email protected] lat: 30.06263 lon: 31.24967 hasResults: False |
<|newrecord|> nctId: NCT06382961 id: SZUS_231101 briefTitle: Postoperative Dexmedetomidine in Prevention of Postoperative Delirium overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-11 date: 2024-03-06 date: 2024-04 date: 2024-04-25 date: 2024-04-25 name: Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. class: INDUSTRY name: Shenzhen People's Hospital name: Dongyuan People's Hospital name: Kunming Children's Hospital briefSummary: The goal of this clinical trial is to learn how postoperative infusion of dexmedetomidine would influence postoperative delirium in elderly patients undergoing lung surgery. The main questions it aims to answer are : |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.